Abstract
Genetic and environmental factors seem to interact and influence both the onset and the course of obsessive–compulsive disorder (OCD), but the role of glutamate transporter variants (SLC1A1) in pharmacological resistance is not known. We aimed to assess whether genetic variants in SLC1A1 and life stress at onset of the disorder interact and modulate pharmacological resistance in OCD. A single-marker association study of several single-nucleotide polymorphisms in the SLC1A1 genomic region was performed in a sample of 238 OCD patients. For the most strongly associated SNP (rs3087879), one copy of the risk allele increased the probability of higher treatment resistance (odds ratio=2.42; 95% confidence interval=1.39–4.21; P=0.0018), but only in OCD patients without life stress at onset of the disorder. These results suggest a gene-by-environment interaction effect on treatment resistance in OCD and strengthen the existing evidence of the role of the glutamatergic system in the phenomenology of OCD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Karno M, Golding JM, Sorenson SB, Burnam MA . The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45: 1094–1099.
Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK et al. The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry 1994; 55 (Suppl): 5–10.
Nestadt G, Samuels J, Riddle M, Bienvenu III OJ, Liang KY, LaBuda M et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 358–363.
Pauls DL, Alsobrook II JP, Goodman W, Rasmussen S, Leckman JF . A family study of obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 76–84.
Hudziak JJ, Van Beijsterveldt CE, Althoff RR, Stanger C, Rettew DC, Nelson EC et al. Genetic and environmental contributions to the Child Behavior Checklist Obsessive-Compulsive Scale: a cross-cultural twin study. Arch Gen Psychiatry 2004; 61: 608–616.
van Grootheest DS, Cath DC, Beekman AT, Boomsma DI . Twin studies on obsessive-compulsive disorder: a review. Twin Res Hum Genet 2005; 8: 450–458.
Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009; 66: 966–975.
Pallanti S, Hollander E, Goodman WK . A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 2004; 65 (Suppl 14): 6–10.
Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L . Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J 2002; 2: 176–181.
Real E, Gratacos M, Soria V, Escaramis G, Alonso P, Segalas C et al. A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. Biol Psychiatry 2009; 66: 674–680.
Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG . Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 2007; 68: 747–753.
Di Bella D, Cavallini MC, Bellodi L . No association between obsessive-compulsive disorder and the 5-HT(1Dbeta) receptor gene. Am J Psychiatry 2002; 159: 1783–1785.
Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL . Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 769–776.
Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 2006; 63: 778–785.
Samuels J, Wang Y, Riddle MA, Greenberg BD, Fyer AJ, McCracken JT et al. Comprehensive family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 472–477.
Shugart YY, Samuels J, Willour VL, Grados MA, Greenberg BD, Knowles JA et al. Genomewide linkage scan for obsessive-compulsive disorder: evidence for susceptibility loci on chromosomes 3q, 7p, 1q, 15q, and 6q. Mol Psychiatry 2006; 11: 763–770.
Stewart SE, Fagerness JA, Platko J, Smoller JW, Scharf JM, Illmann C et al. Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 1027–1033.
Wendland JR, Moya PR, Timpano KR, Anavitarte AP, Kruse MR, Wheaton MG et al. A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch Gen Psychiatry 2009; 66: 408–416.
Wang Y, Samuels JF, Chang YC, Grados MA, Greenberg BD, Knowles JA et al. Gender differences in genetic linkage and association on 11p15 in obsessive-compulsive disorder families. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 33–40.
Samuels JF . Recent advances in the genetics of obsessive-compulsive disorder. Curr Psychiatry Rep 2009; 11: 277–282.
Ting JT, Feng G . Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Curr Chem Genomics 2008; 2: 62–75.
Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ . Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000; 39: 1096–1103.
Yucel M, Wood SJ, Wellard RM, Harrison BJ, Fornito A, Pujol J et al. Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder. Aust N Z J Psychiatry 2008; 42: 467–477.
Ciranna L . Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology. Curr Neuropharmacol 2006; 4: 101–114.
Carlsson ML . On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr Scand 2000; 102: 401–413.
Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005; 58: 424–428.
Grant P, Lougee L, Hirschtritt M, Swedo SE . An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007; 17: 761–767.
Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol 2010; 30: 34–39.
Miguel EC, Leckman JF, Rauch S, do Rosario-Campos MC, Hounie AG, Mercadante MT et al. Obsessive-compulsive disorder phenotypes: implications for genetic studies. Mol Psychiatry 2005; 10: 258–275.
Gothelf D, Aharonovsky O, Horesh N, Carty T, Apter A . Life events and personality factors in children and adolescents with obsessive-compulsive disorder and other anxiety disorders. Compr Psychiatry 2004; 45: 192–198.
Lochner C, du Toit PL, Zungu-Dirwayi N, Marais A, van Kradenburg J, Seedat S et al. Childhood trauma in obsessive-compulsive disorder, trichotillomania, and controls. Depress Anxiety 2002; 15: 66–68.
Cath DC, van Grootheest DS, Willemsen G, van Oppen P, Boomsma DI . Environmental factors in obsessive-compulsive behavior: evidence from discordant and concordant monozygotic twins. Behav Genet 2008; 38: 108–120.
Cromer KR, Schmidt NB, Murphy DL . An investigation of traumatic life events and obsessive-compulsive disorder. Behav Res Ther 2007; 45: 1683–1691.
Maina G, Albert U, Bogetto F, Vaschetto P, Ravizza L . Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res 1999; 89: 49–58.
Real E, Labad J, Alonso P, Segalas C, Jimenez-Murcia S, Bueno B et al. Stressful life events at onset of obsessive-compulsive disorder are associated with a distinct clinical pattern. Depress Anxiety 2011; 28: 367–376.
Albert U, Maina G, Ravizza L, Bogetto F . An exploratory study on obsessive-compulsive disorder with and without a familial component: are there any phenomenological differences? Psychopathology 2002; 35: 8–16.
Labad J, Alonso P, Segalas C, Real E, Jimenez S, Bueno B et al. Distinct correlates of hoarding and cleaning symptom dimensions in relation to onset of obsessive-compulsive disorder at menarche or the perinatal period. Arch Womens Ment Health 2010; 13: 75–81.
Gottesman II, Gould TD . The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636–645.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press: Washington, DC, 1994.
First N, Spitzer R, Gibbon M, Williams J . Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV). American Psychiatric Press: Washington, DC, 1997.
Andreasen NC, Endicott J, Spitzer RL, Winokur G . The family history method using diagnostic criteria. Reliability and validity. Arch Gen Psychiatry 1977; 34: 1229–1235.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006–1011.
Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, Leckman JF . Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 2008; 165: 1532–1542.
Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB . Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007; 164 (7 Suppl): 5–53.
Pallanti S, Quercioli L . Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 400–412.
Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002; 5: 181–191.
Paykel ES, Prusoff BA, Uhlenhuth EH . Scaling of life events. Arch Gen Psychiatry 1971; 25: 340–347.
Bogetto F, Venturello S, Albert U, Maina G, Ravizza L . Gender-related clinical differences in obsessive-compulsive disorder. Eur Psychiatry 1999; 14: 434–441.
Alonso P, Gratacos M, Segalas C, Escaramis G, Real E, Bayes M et al. Variants in estrogen receptor alpha gene are associated with phenotypical expression of obsessive-compulsive disorder. Psychoneuroendocrinology 2011; 36: 473–483.
Rosario-Campos MC, Leckman JF, Mercadante MT, Shavitt RG, Prado HS, Sada P et al. Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry 2001; 158: 1899–1903.
Alarcon RD, Libb JW, Spitler D . A predictive study of obsessive-compulsive disorder response to clomipramine. J Clin Psychopharmacol 1993; 13: 210–213.
Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L . Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 1999; 156: 1409–1416.
Hanna GL, Veenstra-VanderWeele J, Cox NJ, Boehnke M, Himle JA, Curtis GC et al. Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. Am J Med Genet 2002; 114: 541–552.
Willour VL, Yao Shugart Y, Samuels J, Grados M, Cullen B, Bienvenu III OJ et al. Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. Am J Hum Genet 2004; 75: 508–513.
Bergles DE, Jahr CE . Synaptic activation of glutamate transporters in hippocampal astrocytes. Neuron 1997; 19: 1297–1308.
Lipton SA, Rosenberg PA . Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613–622.
Rotge JY, Aouizerate B, Tignol J, Bioulac B, Burbaud P, Guehl D . The glutamate-based genetic immune hypothesis in obsessive-compulsive disorder. An integrative approach from genes to symptoms. Neuroscience 2010; 165: 408–417.
Weinshilboum R . Inheritance and drug response. N Engl J Med 2003; 348: 529–537.
Binder EB, Holsboer F . Pharmacogenomics and antidepressant drugs. Ann Med 2006; 38: 82–94.
Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC . Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 1995; 52: 53–60.
Poyurovsky M, Weizman R, Weizman A, Koran L . Memantine for treatment-resistant OCD. Am J Psychiatry 2005; 162: 2191–2192.
Pittenger C, Bloch MH, Williams K . Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 2011; 132: 314–332.
McGough JJ . Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 2005; 57: 1367–1373.
Wong ML, Licinio J . From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004; 3: 136–151.
Zobel A, Maier W . Pharmacogenetics of antidepressive treatment. Eur Arch Psychiatry Clin Neurosci 2010; 260: 407–417.
Monroe SM . Modern approaches to conceptualizing and measuring human life stress. Annu Rev Clin Psychol 2008; 4: 33–52.
Acknowledgements
Financial support was received from the Spanish Ministry of Health, Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias de la Seguridad Social (PI10/01753, PI10/01003, CIBER-CB06/03/0034), the Ministry of Science and Innovation, MICINN (SAF2008-00357), the ‘Centro de Investigación en Red en Epidemiología y Salud Pública’, CIBERESP (PI050960; PI000954; PI040632 and PI040619), the Department of Health and the Department of Universities Research and Information Society of the Generalitat de Catalunya (2009SGR1554). JL has received an Intensification of Research Activity grant (Programme I3SNS-INT 11/323) from the Instituto de Salud Carlos III (Spain) during 2012. ER was funded by the Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). We thank all the study participants and staff from the Department of Psychiatry of the Hospital Universitari de Bellvitge who helped to obtain the study sample. We also thank Michael Maudsley for help with the English.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Real, E., Gratacòs, M., Labad, J. et al. Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive–compulsive disorder. Pharmacogenomics J 13, 470–475 (2013). https://doi.org/10.1038/tpj.2012.30
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2012.30